ReviewThe Lancet regional health. Western Pacific2022
Reducing liver disease-related deaths in the Asia-Pacific: the important role of decentralised and non-specialist led hepatitis C treatment for cirrhotic patients.
Review in The Lancet regional health. Western Pacific, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Emerging roles of circular RNAs and enhancer RNAs: new insights into the development and management of neurodegenerative disorders.Biomarker research · 2026Review
- Changes in DNA Methylation Associated With Psychobehavioral Interventions: A Scoping Literature Review.Biological research for nursing · 2025Article
- Exploring the electrical and magnetic characteristics of novel barium-doped bismuth ferrite (BiRSC advances · 2025Article
- Lipidic Nanosystem as State-of-the-Art Nanovehicle for Biomedical Applications.Indian journal of microbiology · 2024Review
- Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study.The lancet. Gastroenterology & hepatology · 2024Article
- Patients' experience of accessing hepatitis C treatment through the Myanmar national hepatitis C treatment program: a qualitative evaluation.BMC health services research · 2024Article
- QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- The Prevalence and Clinical Features of Co-Infection with SARS-CoV-2 and Influenza Virus during the COVID-19 Pandemic in Semnan, Iran.Medical journal of the Islamic Republic of Iran · 2024Article
- Oxygen generating biomaterials at the forefront of regenerative medicine: advances in bone regeneration.Frontiers in bioengineering and biotechnology · 2024Review
- Exploring Extremophiles from Bulgaria: Biodiversity, Biopolymer Synthesis, Functional Properties, Applications.Polymers · 2023Review
- Spatial-temporal analysis and spatial drivers of hepatitis-related deaths in 183 countries, 2000-2019.Scientific reports · 2023Article
- Observational
- Biological, pathological, and multifaceted therapeutic functions of exosomes to target cancer.Oncology research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.